Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

PURPOSE: We evaluated longitudinal tracking of BRAF V600E in circulating cell-free DNA (cfDNA) as a marker of treatment response to BRAF inhibitor (BRAFi) combination therapies in non-melanoma solid tumors included in the Copenhagen Prospective Personalized Oncology (CoPPO) program. EXPERIMENTAL DES...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahlborn, Lise Barlebo, Tuxen, Ida Viller, Mouliere, Florent, Kinalis, Savvas, Schmidt, Ane Y., Rohrberg, Kristoffer Staal, Santoni-Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik, Yde, Christina Westmose, Oestrup, Olga, Mau-Sorensen, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135692/
https://www.ncbi.nlm.nih.gov/pubmed/30220966
http://dx.doi.org/10.18632/oncotarget.25948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135692/
https://www.ncbi.nlm.nih.gov/pubmed/30220966
http://dx.doi.org/10.18632/oncotarget.25948

Ejemplares similares